| De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells |
Olivia Bawa, Jean Yves Scoazec |
01/12/2022
|
Molecular Cancer |
| Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test |
Damien Vasseur, Etienne Rouleau, Ludovic Lacroix |
01/06/2022
|
Cells |
| The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies |
Ludovic Lacroix, Sophie Cotteret, Jean Yves Scoazec |
01/05/2022
|
Cancer Discovery |
| Cancer stem-like cells evade CD8<sup>+</sup>CD103<sup>+</sup> tumor-resident memory T (T<inf>RM</inf>) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor model |
Aziza Caidi, Marc Deloger |
13/04/2022
|
Journal for ImmunoTherapy of Cancer |
| Therapeutic potential of the human endogenous retroviral envelope protein HEMO: a pan-cancer analysis |
Olivia Bawa, Bastien Job, Jean Yves Scoazec |
01/04/2022
|
Molecular Oncology |
| Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients |
Damien Vasseur, Ludovic Lacroix, Jean Yves Scoazec |
01/04/2022
|
Annals of Oncology |
| Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial |
Marie Naigeon, Lydie Cassard, Lisa Boselli, Jonathan Grivel, Ludovic Lacroix, Nathalie Chaput |
01/04/2022
|
Lung Cancer |
| TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy |
Nicolas Signolle |
17/03/2022
|
Journal for ImmunoTherapy of Cancer |
| Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy |
Jean Yves Scoazec |
14/03/2022
|
Cancer Cell |
| CD8<sup>+</sup>PD-1<sup>+</sup> to CD4<sup>+</sup>PD-1<sup>+</sup> ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers |
Boris Duchemann, Marie Naigeon, Lydie Cassard, Jean Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, Nathalie Chaput |
07/02/2022
|
Journal for ImmunoTherapy of Cancer |
| Diagnostic accuracy of in vivo early tumor imaging from probe-based confocal laser endomicroscopy versus histologic examination in head and neck squamous cell carcinoma |
Muriel Abbaci, Frederic De Leeuw, Corinne Laplace-Builhe |
01/02/2022
|
Clinical Oral Investigations |
| Adoptive cell therapies in thoracic malignancies |
Marie Naigeon, Nathalie Chaput, Boris Duchemann |
01/01/2022
|
Cancer Immunology, Immunotherapy |
| Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer |
Damien Vasseur, Cécile Jovelet, Etienne Rouleau, Ludovic Lacroix |
01/01/2022
|
Clinical Lung Cancer |
| A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients |
Virginie Marty |
01/01/2022
|
OncoImmunology |
| Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade |
Nathalie Chaput |
15/12/2021
|
Clinical Cancer Research |
| Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms |
Cyril Catelain, Philippe Rameau |
02/12/2021
|
Blood |
| Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation |
Kadija Diop, Nathalie Droin |
01/12/2021
|
European Journal of Cancer |
| Serial transplantation unmasks galectin-9 contribution to tumor immune escape in the MB49 murine model |
Olivia Bawa, Nicolas Signolle, M’boyba K. Diop, Philippe Dessen |
01/12/2021
|
Scientific Reports |
| Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance |
Nathalie Chaput |
01/11/2021
|
Annals of Oncology |
| First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial |
Ludovic Lacroix |
01/11/2021
|
European Journal of Cancer |
